PMC:7212965 / 936-1785 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T4","span":{"begin":81,"end":86},"obj":"Body_part"},{"id":"T5","span":{"begin":760,"end":765},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma7197"}],"text":"led the prevalence of diarrhea, nausea, vomiting, and abdominal pain, as well as liver function tests abnormalities, using a fixed-effect model and assessed the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework.\n\nResults\nWe identified 118 studies and used a hierarchal study selection process to identify unique cohorts. We performed a meta-analysis of 47 studies including 10,890 unique patients. Pooled prevalence estimates of GI symptoms were as follows: diarrhea 7.7% (95% confidence interval [CI], 7.2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) a"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T4","span":{"begin":81,"end":86},"obj":"Body_part"},{"id":"T5","span":{"begin":760,"end":765},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"}],"text":"led the prevalence of diarrhea, nausea, vomiting, and abdominal pain, as well as liver function tests abnormalities, using a fixed-effect model and assessed the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework.\n\nResults\nWe identified 118 studies and used a hierarchal study selection process to identify unique cohorts. We performed a meta-analysis of 47 studies including 10,890 unique patients. Pooled prevalence estimates of GI symptoms were as follows: diarrhea 7.7% (95% confidence interval [CI], 7.2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) a"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T7","span":{"begin":22,"end":30},"obj":"Disease"},{"id":"T8","span":{"begin":524,"end":532},"obj":"Disease"}],"attributes":[{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"}],"text":"led the prevalence of diarrhea, nausea, vomiting, and abdominal pain, as well as liver function tests abnormalities, using a fixed-effect model and assessed the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework.\n\nResults\nWe identified 118 studies and used a hierarchal study selection process to identify unique cohorts. We performed a meta-analysis of 47 studies including 10,890 unique patients. Pooled prevalence estimates of GI symptoms were as follows: diarrhea 7.7% (95% confidence interval [CI], 7.2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) a"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T9","span":{"begin":81,"end":86},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T10","span":{"begin":81,"end":86},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T11","span":{"begin":96,"end":101},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T12","span":{"begin":123,"end":124},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T13","span":{"begin":322,"end":323},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T14","span":{"begin":400,"end":401},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T15","span":{"begin":760,"end":765},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T16","span":{"begin":760,"end":765},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"}],"text":"led the prevalence of diarrhea, nausea, vomiting, and abdominal pain, as well as liver function tests abnormalities, using a fixed-effect model and assessed the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework.\n\nResults\nWe identified 118 studies and used a hierarchal study selection process to identify unique cohorts. We performed a meta-analysis of 47 studies including 10,890 unique patients. Pooled prevalence estimates of GI symptoms were as follows: diarrhea 7.7% (95% confidence interval [CI], 7.2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) a"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T3","span":{"begin":495,"end":497},"obj":"Chemical"},{"id":"T4","span":{"begin":797,"end":806},"obj":"Chemical"}],"attributes":[{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_73907"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_132943"},{"id":"A5","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_29995"},{"id":"A6","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_72314"}],"text":"led the prevalence of diarrhea, nausea, vomiting, and abdominal pain, as well as liver function tests abnormalities, using a fixed-effect model and assessed the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework.\n\nResults\nWe identified 118 studies and used a hierarchal study selection process to identify unique cohorts. We performed a meta-analysis of 47 studies including 10,890 unique patients. Pooled prevalence estimates of GI symptoms were as follows: diarrhea 7.7% (95% confidence interval [CI], 7.2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) a"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T4","span":{"begin":22,"end":30},"obj":"Phenotype"},{"id":"T5","span":{"begin":32,"end":48},"obj":"Phenotype"},{"id":"T6","span":{"begin":54,"end":68},"obj":"Phenotype"},{"id":"T7","span":{"begin":524,"end":532},"obj":"Phenotype"},{"id":"T8","span":{"begin":581,"end":596},"obj":"Phenotype"},{"id":"T9","span":{"begin":627,"end":641},"obj":"Phenotype"},{"id":"T10","span":{"begin":760,"end":779},"obj":"Phenotype"}],"attributes":[{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0002017"},{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0002027"},{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0002017"},{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0002027"},{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0001392"}],"text":"led the prevalence of diarrhea, nausea, vomiting, and abdominal pain, as well as liver function tests abnormalities, using a fixed-effect model and assessed the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework.\n\nResults\nWe identified 118 studies and used a hierarchal study selection process to identify unique cohorts. We performed a meta-analysis of 47 studies including 10,890 unique patients. Pooled prevalence estimates of GI symptoms were as follows: diarrhea 7.7% (95% confidence interval [CI], 7.2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) a"}

{"project":"LitCovid-sentences","denotations":[{"id":"T9","span":{"begin":279,"end":286},"obj":"Sentence"},{"id":"T10","span":{"begin":287,"end":386},"obj":"Sentence"},{"id":"T11","span":{"begin":387,"end":463},"obj":"Sentence"},{"id":"T12","span":{"begin":464,"end":667},"obj":"Sentence"},{"id":"T13","span":{"begin":668,"end":715},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"led the prevalence of diarrhea, nausea, vomiting, and abdominal pain, as well as liver function tests abnormalities, using a fixed-effect model and assessed the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework.\n\nResults\nWe identified 118 studies and used a hierarchal study selection process to identify unique cohorts. We performed a meta-analysis of 47 studies including 10,890 unique patients. Pooled prevalence estimates of GI symptoms were as follows: diarrhea 7.7% (95% confidence interval [CI], 7.2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) a"}

{"project":"LitCovid-PubTator","denotations":[{"id":"34","span":{"begin":22,"end":30},"obj":"Disease"},{"id":"35","span":{"begin":32,"end":38},"obj":"Disease"},{"id":"36","span":{"begin":40,"end":48},"obj":"Disease"},{"id":"37","span":{"begin":54,"end":68},"obj":"Disease"},{"id":"54","span":{"begin":495,"end":497},"obj":"Gene"},{"id":"55","span":{"begin":454,"end":462},"obj":"Species"},{"id":"56","span":{"begin":706,"end":714},"obj":"Species"},{"id":"57","span":{"begin":524,"end":532},"obj":"Disease"},{"id":"58","span":{"begin":581,"end":587},"obj":"Disease"},{"id":"59","span":{"begin":588,"end":596},"obj":"Disease"},{"id":"60","span":{"begin":627,"end":641},"obj":"Disease"},{"id":"61","span":{"begin":751,"end":779},"obj":"Disease"}],"attributes":[{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"MESH:D003967"},{"id":"A35","pred":"tao:has_database_id","subj":"35","obj":"MESH:D009325"},{"id":"A36","pred":"tao:has_database_id","subj":"36","obj":"MESH:D014839"},{"id":"A37","pred":"tao:has_database_id","subj":"37","obj":"MESH:D015746"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"Gene:2770"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"Tax:9606"},{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"Tax:9606"},{"id":"A57","pred":"tao:has_database_id","subj":"57","obj":"MESH:D003967"},{"id":"A58","pred":"tao:has_database_id","subj":"58","obj":"MESH:D009325"},{"id":"A59","pred":"tao:has_database_id","subj":"59","obj":"MESH:D014839"},{"id":"A60","pred":"tao:has_database_id","subj":"60","obj":"MESH:D015746"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"MESH:D006973"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"led the prevalence of diarrhea, nausea, vomiting, and abdominal pain, as well as liver function tests abnormalities, using a fixed-effect model and assessed the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework.\n\nResults\nWe identified 118 studies and used a hierarchal study selection process to identify unique cohorts. We performed a meta-analysis of 47 studies including 10,890 unique patients. Pooled prevalence estimates of GI symptoms were as follows: diarrhea 7.7% (95% confidence interval [CI], 7.2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) a"}